z-logo
Premium
Exome sequencing as a second‐tier diagnostic approach for clinically suspected dysferlinopathy patients
Author(s) -
Bartoli Marc,
Desvignes JeanPierre,
Nicolas Levy,
Martin Krahn
Publication year - 2014
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.24344
Subject(s) - exome sequencing , medicine , dysferlin , exome , pediatrics , mutation , genetics , biology , muscular dystrophy , gene
: Autosomal recessive muscular dystrophies are heterogeneous genetic disorders, with 39 genes currently implicated. Genetic diagnosis using targeted single‐gene analysis by Sanger sequencing yields negative results in 10−20% of samples, warranting clinical re‐evaluation and time‐consuming testing of additional genes. This applies to dysferlinopathies caused by mutations in the gene encoding dysferlin ( DYSF ), which presents mainly as limb‐girdle muscular dystrophy (LGMD) or distal myopathy. Methods : We evaluated exome sequencing associated with data filtering for selected genes as a second‐tier approach for genetic diagnosis in a cohort of 37 patients with an initial negative result on targeted DYSF analysis. Results : Exome sequencing allowed for establishing (16%) or suggesting (8%) the molecular diagnosis by implicating other known LGMD or distal myopathy genes or by revealing DYSF mutations previously missed using mutation‐screening techniques with incomplete detection yields. Conclusions : Exome sequencing associated with data filtering constitutes an efficient second‐tier analysis for genes implicated in LGMD or distal myopathies. Muscle Nerve 50: 1007–1010, 2014

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom